Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
HOME > REGULATORY
REGULATORY
- Average NHI-Market Price Gap at “Around 8%”, MHLW Reveals to LDP Bigwigs; Total Savings Undisclosed
December 3, 2019
- Ryukaikon’s Dec. 9 Meeting Likely to Be Put Off in Wake of Bid-Rigging Scandal
December 3, 2019
- Causal Link between Eisai’s Epilepsy Drug and Trial Death Can’t Be Ruled Out: MHLW
December 2, 2019
- MHLW Panel OKs Eisai’s Insomnia Med, Fycompa’s Monotherapy and More
December 2, 2019
- Use of Antibiotics in Japan Down 10.6% in 2018 vs. 2013: MHLW
December 2, 2019
- Komeito Calls for System to Reward Useful New Indications
November 29, 2019
- Japan Pharma Industry Chief Raises Alarm over Comparator PMP Deduction Proposal: LDP Study Group
November 29, 2019
- Govt Panel to Draw Up New AMR Action Plan for 2021 and Beyond
November 29, 2019
- Amended PMD Law Set for 3-Step Enforcement, 1st Execution Eyed Next Autumn
November 28, 2019
- LDP to Forge Lawmakers’ League Aimed to Reinstate HPV Vaccine Recommendation
November 27, 2019
- “All-Generation” Panel Cites Coverage of OTC-Like Drugs as Policy Issue
November 27, 2019
- Japan Enacts Amended Pharmaceuticals and Medical Devices Law
November 27, 2019
- Japan’s First Biosimilars of Avastin, Nesp, Forteo Receive Listing
November 27, 2019
- MOF Panel Leery of Pricey Drugs for Huge Patient Population: FY2020 Budget Recommendation
November 26, 2019
- MHLW Panel OKs Bayer’s Xtandi Rival, AbbVie’s JAK Inhibitor; 2 More Keytruda Usages Now in Line for Approval
November 26, 2019
- MHLW Panel Members Call for Need to “at Least Discuss” Whether to Resume Actively Recommending HPV Vaccines
November 26, 2019
- Plaintiffs of HPV Vaccine Suits Prod JMA to Hear Stories of Victims
November 26, 2019
- MHLW Floats 2 Rules to Address Unreasonable Price Rises for Listed Generics
November 26, 2019
- Xolair’s Pollen Allergy Nod Delayed as Novartis Says It Needs More Time to Prepare for Launch
November 25, 2019
- Chuikyo Members Remain Divided over Timing of Comparator PMP Removal
November 25, 2019
ページ
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Indian generic maker Lupin is casting off Kyowa Pharmaceutical Industry, which it acquired in 2007. Forking over 57.4 billion yen…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
While the digital transformation may only be in its infancy in the pharmaceutical industry, the winds of change are here. It’s only a matter of time until customers and patients demand a higher level of service, experience, and connectivity from…